Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX2735 pilot study in recurrent pericarditis
2025-524784-20-00Phase 2Authorised
- Sponsor
- Zomagen Biosciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of VTX2735 in recurrent pericarditis, sponsored by Zomagen Biosciences. Primary endpoint: Incidence and severity of adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
VTX2735
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on 2025-524784-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524784-20-00.